Literature DB >> 10193424

Asymptomatic Borrelia-seropositive individuals display the same incidence of Borrelia-specific interferon-gamma (IFN-gamma)-secreting cells in blood as patients with clinical Borrelia infection.

C Ekerfelt1, P Forsberg, M Svenvik, M Roberg, S Bergström, J Ernerudh.   

Abstract

Borrelia Lyme disease is a complex disorder that sometimes becomes chronic. There are contradictory reports of experimental Borrelia infections regarding which type of T cell cytokine responses, i.e. Th1 or Th2, are needed to eradicate the Borrelia spirochaetes. In human borreliosis a predominance of Borrelia-specific Th1-like responses has been shown. In this study, spontaneous, as well as Borrelia-specific, secretion of IFN-gamma (Th1) and IL-4 (Th2) in Borrelia-seropositive healthy asymptomatic individuals (n = 17) was investigated in peripheral blood by a sensitive ELISPOT assay, and compared with previously reported responses in patients with clinical Borrelia infection (n = 25). The seropositive asymptomatic individuals displayed the same predominance of Borrelia-specific IFN-gamma-secreting cells as the patients with clinical Borrelia infection. Interestingly, the proportion of spontaneously IL-4-secreting cells, reflecting the unstimulated in vivo secretion, was lower in the seropositive asymptomatic individuals compared with patients with chronic Borrelia infections (n = 13, P = 0.02), whereas no such difference was found compared with subacute Borrelia infections (n = 12). These findings indicate that IFN-gamma secretion alone is not sufficient to eliminate Borrelia spirochaetes in humans, although IFN-gamma may still have a beneficial role in borreliosis acting in concert with other mechanisms.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10193424      PMCID: PMC1905261          DOI: 10.1046/j.1365-2249.1999.00840.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  26 in total

1.  Heterogeneity of major proteins in Lyme disease borreliae: a molecular analysis of North American and European isolates.

Authors:  A G Barbour; R A Heiland; T R Howe
Journal:  J Infect Dis       Date:  1985-09       Impact factor: 5.226

2.  Enzyme-linked immunosorbent assays for Lyme disease: reactivity of subunits of Borrelia burgdorferi.

Authors:  L A Magnarelli; J F Anderson; A G Barbour
Journal:  J Infect Dis       Date:  1989-01       Impact factor: 5.226

3.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

4.  Recombinant IL-4 treatment augments resistance to Borrelia burgdorferi infections in both normal susceptible and antibody-deficient susceptible mice.

Authors:  A Keane-Myers; C R Maliszewski; F D Finkelman; S P Nickell
Journal:  J Immunol       Date:  1996-04-01       Impact factor: 5.422

5.  T helper type 2 like cytokine responses to peptides from P0 and P2 myelin proteins during the recovery phase of Guillain-Barré syndrome.

Authors:  C Dahle; C Ekerfelt; M Vrethem; M Samuelsson; J Ernerudh
Journal:  J Neurol Sci       Date:  1997-12-09       Impact factor: 3.181

6.  Chronic Lyme arthritis. Clinical and immunogenetic differentiation from rheumatoid arthritis.

Authors:  A C Steere; A Gibofsky; M E Patarroyo; R J Winchester; J A Hardin; S E Malawista
Journal:  Ann Intern Med       Date:  1979-06       Impact factor: 25.391

Review 7.  Lyme disease.

Authors:  A C Steere
Journal:  N Engl J Med       Date:  1989-08-31       Impact factor: 91.245

8.  Lyme neuroborreliosis: evidence for persistent up-regulation of Borrelia burgdorferi-reactive cells secreting interferon-gamma.

Authors:  W Z Wang; S Fredrikson; J B Sun; H Link
Journal:  Scand J Immunol       Date:  1995-12       Impact factor: 3.487

9.  An epidemiologic study of Lyme disease in southern Sweden.

Authors:  J Berglund; R Eitrem; K Ornstein; A Lindberg; A Ringér; H Elmrud; M Carlsson; A Runehagen; C Svanborg; R Norrby
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

10.  Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism.

Authors:  M D Sadick; F P Heinzel; B J Holaday; R T Pu; R S Dawkins; R M Locksley
Journal:  J Exp Med       Date:  1990-01-01       Impact factor: 14.307

View more
  15 in total

1.  Mercury exposure as a model for deviation of cytokine responses in experimental Lyme arthritis: HgCl2 treatment decreases T helper cell type 1-like responses and arthritis severity but delays eradication of Borrelia burgdorferi in C3H/HeN mice.

Authors:  C Ekerfelt; M Andersson; A Olausson; S Bergström; P Hultman
Journal:  Clin Exp Immunol       Date:  2007-08-02       Impact factor: 4.330

2.  Reduced number of interleukin-12 secreting cells in patients with Lyme borreliosis previously exposed to Anaplasma phagocytophilum.

Authors:  S Jarefors; M Karlsson; P Forsberg; I Eliasson; J Ernerudh; C Ekerfelt
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

3.  Decreased up-regulation of the interleukin-12Rbeta2-chain and interferon-gamma secretion and increased number of forkhead box P3-expressing cells in patients with a history of chronic Lyme borreliosis compared with asymptomatic Borrelia-exposed individuals.

Authors:  S Jarefors; C K Janefjord; P Forsberg; M C Jenmalm; C Ekerfelt
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

4.  Lyme borreliosis reinfection: might it be explained by a gender difference in immune response?

Authors:  Sara Jarefors; Louise Bennet; Elin You; Pia Forsberg; Christina Ekerfelt; Johan Berglund; Jan Ernerudh
Journal:  Immunology       Date:  2006-06       Impact factor: 7.397

5.  Innate immune responses in Lyme borreliosis: enhanced tumour necrosis factor-alpha and interleukin-12 in asymptomatic individuals in response to live spirochetes.

Authors:  J Sjöwall; A Carlsson; O Vaarala; S Bergström; J Ernerudh; P Forsberg; C Ekerfelt
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

6.  Borrelia infection and risk of non-Hodgkin lymphoma.

Authors:  Claudia Schöllkopf; Mads Melbye; Lars Munksgaard; Karin Ekström Smedby; Klaus Rostgaard; Bengt Glimelius; Ellen T Chang; Göran Roos; Mads Hansen; Hans-Olov Adami; Henrik Hjalgrim
Journal:  Blood       Date:  2008-04-18       Impact factor: 22.113

7.  Doxycycline-mediated effects on persistent symptoms and systemic cytokine responses post-neuroborreliosis: a randomized, prospective, cross-over study.

Authors:  Johanna Sjöwall; Anna Ledel; Jan Ernerudh; Christina Ekerfelt; Pia Forsberg
Journal:  BMC Infect Dis       Date:  2012-08-10       Impact factor: 3.090

8.  Decreased Th1-type inflammatory cytokine expression in the skin is associated with persisting symptoms after treatment of erythema migrans.

Authors:  Johanna Sjöwall; Linda Fryland; Marika Nordberg; Florence Sjögren; Ulf Garpmo; Christian Jansson; Sten-Anders Carlsson; Sven Bergström; Jan Ernerudh; Dag Nyman; Pia Forsberg; Christina Ekerfelt
Journal:  PLoS One       Date:  2011-03-31       Impact factor: 3.240

9.  Clinical, diagnostic and immunological characteristics of patients with possible neuroborreliosis without intrathecal Ig-synthesis against Borrelia antigen in the cerebrospinal fluid.

Authors:  Magnus Vrethem; Mona Widhe; Jan Ernerudh; Ulf Garpmo; Pia Forsberg
Journal:  Neurol Int       Date:  2011-04-08

10.  The lymphocyte transformation test for borrelia detects active lyme borreliosis and verifies effective antibiotic treatment.

Authors:  Volker von Baehr; Cornelia Doebis; Hans-Dieter Volk; Rüdiger von Baehr
Journal:  Open Neurol J       Date:  2012-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.